Aegon is Europe's largest insurance company based out of Norway. It was once a $60 stock in 2001-2002. It is now trading at $4-5 and the reason is that financials all over have been beaten up. This company has pledged to meet their future targets. My personal target for the stock is $10. It highly undervalued on so many levels and they have tightened the screws to create a leaner financials services company. I found the stock on one of my value investment screeners and I have been adding to my position week after week. I feel very comfortable about the risk/reward when it comes to Aegon as an investment. I also believe that divideneds will return for those of us that are loyal investors. Lets see where the company is in three years.
https://www.google.com/finance?client=ob&q=NYSE:AEG
Sunday, January 22, 2012
Wednesday, June 10, 2009
Peregrine Pharmaceuticals PPHM gets ASCO award
Reprinted from cjgaddy post on the Silicon Investor website.
Another drop in the hat for PPHM, and boy is it nice to see an ASCO award go to them. With a promising cancer drug like Bavituximab...well you would be hard pressed to find another company quite like this one. Anyway here is the post.
---
PR 6-10-09: ASCO Award to UTSW for New Bavi/NSCLC Study
“ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer”
• Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr. David Gerber of UT Southwestern Medical Center
• New Study Complements Ongoing Bavituximab + Carboplatin/Paclitaxel Phase II NSCLC Trial that has Shown Promising Preliminary Results
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=388927
TUSTIN, June 10 2009: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the ASCO Research Foundation has awarded one of its 2009 Career Development Awards to David Gerber, MD, of the University of Texas Southwestern Medical Center for a study of the biologic effects of bavituximab & chemotherapy in patients with advanced lung cancer. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects.
This new study will supplement Peregrine's Phase II clinical trial [India] evaluating bavituximab in combination with carboplatin & paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). In the first cohort of this trial, 11 of 17 evaluable NSCLC patients, or 64.7%, achieved an objective tumor response according to response evaluation criteria in solid tumors (RECIST). Enrollment of an additional 28 NSCLC patients is ongoing.
"We are delighted that the ASCO Research Foundation has selected Dr. Gerber's study for this prestigious award that nicely complements our ongoing Phase II NSCLC trial, which has already shown very promising results," said Steven W. King, president and CEO of Peregrine. "This clinical study should help us to better understand the biological effects of this new class of immunotherapeutic agents and generate data that will help guide the future clinical development and use of bavituximab."
Dr. Gerber, assistant professor at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern, will receive a 3-year award totaling $200,000 to support his original research, A Pilot Study of the Biologic Effects of Chemotherapy Plus Bavituximab in Patients with Advanced Non-Small Cell Lung Cancer. These competitive awards are available to promising physician researchers who are full-time faculty members in a clinical setting at an academic medical center.
Bavituximab is also currently being tested in combination with chemotherapy in two Phase II trials in advanced breast cancer. Preliminary positive results from one of these trials were the subject of an oral presentation at the 2009 ASCO Annual Meeting.
ABOUT PHOSPHATIDYLSERINE (PS)-TARGETING IMMUNOTHERAPIES
The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at http://www.peregrineinc.com.
ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing 3 separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor *snip*
Contacts: GendeLLindheim BioCom Partners
Investors: 800-987-8256, info@peregrineinc.com
Media: Barbara Lindheim, 212-918-4650
*end*
= = = = = = = = =
Recall, on 4-3-09, the NCI Trials website showed UTSW/Dallas being added as a 5th site in the ongoing U.S. Ph.1 Bavi-Mono Solid Tumors trial, with Dr. Gerber as PI:
Ph.1 Trial: “Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies”
Last Updated: April 3, 2009
TRIAL LOCATIONS:
ADDED:
University of Texas SW Medical Center/Dallas - Recruiting
Principal Investigator: David E Gerber, MD
http://clinicaltrials.gov/ct/show/NCT00129337
Dr. David Gerber’s UTSW Profile:
http://www.utsouthwestern.edu/findfac/professional/0,,53487,00.html
Dr. David Gerber authored this 2-2008 article in American Family Physician:
“Targeted Therapies: A New Generation of Cancer Treatments”
DAVID E. GERBER, MD
The two main types of targeted therapy, monoclonal antibodies and small molecule inhibitors, have revolutionized the treatment of cancer. With their distinct mechanisms of action and toxicities, these drugs require new approaches to determine optimal dosing, to assess patient adherence to therapy, and to evaluate treatment effectiveness…
http://www.aafp.org/afp/20080201/contents.html
http://www.aafp.org/afp/20080201/311.html
He has also presented at past ASCO meetings: http://tinyurl.com/d2pgq7
= = = = = = = = = = =
“The ASCO Cancer Foundation Awards $6.1mm to Further Progress Against Cancer”
FOR IMMEDIATE RELEASE: April 15, 2009
http://tinyurl.com/cqhuse
4-15-09, Alexandria, VA: The ASCO Cancer Foundation will award more than $6.1mm to support clinical & translational research designed to improve cancer prevention, treatment and care. The grants will be awarded to 63 researchers at the ASCO’s 45th Annual Meeting in Orlando, May29–June2…
• Translational Research Professorship: $500k, Merrill Egorin, UPitt
• Advanced Clinical Research Awards: $450k, S.Modi/Sloan-Kettering & I.Mellinghoff/Sloan-Kettering
• Career Development Awards: $200k x 11 winners…
Career Development Awards are presented to physicians in their second, third or fourth year as full-time faculty members in a university setting. Each of this year's 11 winners will receive a 3-year grant totaling $200,000 to establish an indep. clinical cancer research program. The 11 2009 recipients are:
. . .
David Gerber, MD – Univ. of Texas, SW Medical Center
“A Pilot Study of the Biologic Effects of Chemotherapy Plus Bavituximab in Patients with Advanced Non-Small Cell Lung Cancer”
. . .
Supporting Organizations:
The 2009 Career Development Awards are supported by: Amgen, Genentech BioOncology (5), Lilly USA, Novartis Oncology, Sanofi-aventis U.S. (2), The Breast Cancer Research Foundation.
About The ASCO Cancer Foundation:
As the charitable arm of the American Society of Clinical Oncology (ASCO), The ASCO Cancer Foundation funds research, education and cancer care programs both in the U.S. and abroad. By harnessing the knowledge of ASCO’s 27,000 oncology professionals, we help deliver physician-approved information directly to those in need. Through these efforts, we improve the lives of those affected by cancer.
= = = = = = = = = = =
EARLY COMPARISONS OF BAVI VS. AVASTIN TRIAL DATA
III. ADV./MET. NSCLC CANCER (India) - MAB + PACLITAXEL/CARBOPLATIN:
Ph.2 Bavi+CP n=17: 64.7% ORR, interim at ~18wks (6 of 6 cycles). http://tinyurl.com/pe923n
• Ph.2 Avastin+CP n=35: 31.5% ORR http://tinyurl.com/b3g4rf (D.H.Johnson)
...”Avastin+CP yielded longer median TTP (7.4 v 4.2 mos.) and a modest increase in survival (17.7 v 14.9 mos.)”
• Ph.2 Antisoma’s ASA404+CP n=30: 37.9% ORR http://tinyurl.com/pcraga
3-18-09/Cowen, P.Lytle comp. to:
• Avastin+CP (Johnson), 31.5% ORR – at best dosage/15mg (n=99 at both dosages) [ 2004 Ph2 http://tinyurl.com/b3g4rf ]
• Avastin+CP (Sandler), 35% ORR (133 of 381) – best resp. reported. [ 2006 Ph2/3 ‘E4599’ http://tinyurl.com/dbvh4e Excl. Squamous**]
**Note: “In prev. clinical experience with Avastin+CP in NSCLC, patients with ‘squamous’ cancer had a higher risk of experiencing life-threatening or fatal pulmonary bleeding. Squamous cells are a kind of cell that form in the lining of the air ducts in the lung. Because of the risk of bleeding attributed to this population, patients with NSCLC classified as predominantly squamous histology were not included in the E4599 trial.” http://tinyurl.com/cfk9ao
- - - - - - - - - - -
**Another Ph.2 NSCLC trial to compare to…
5-21-09: PH.2 RESULTS FOR ANTISOMA’S ASA404+CP VS. NSCLC (N=30): ORR=37.9%
Antisoma announces that the journal Lung Cancer has published the results of a single-arm Ph.2 trial of ASA404 in NSCLC. The trial included patients with both major histological forms of NSCLC: squamous & non-squamous. Positive data from this trial supported the progress of ASA404 into Ph.3 trials in patients with NSCLC of all histologies. ASA404 is a Tumor-Vascular Disrupting Agent (VDA) that destroys tumors by selectively collapsing the tumor blood vessels on which they depend to survive & grow... In the newly published trial, a further 30 similar patients with NSCLC received std. chemo[carboplatin & paclitaxel] + ASA404 at a higher dose of 1800mg. Median survival was 14.9mos… [compared with 8.8mos. in patients receiving chemo alone]… Tumor response rate was 37.9%... TTP was 5.5mos…. Median survival was 14.9mos.
http://tinyurl.com/pcraga
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+DOCE/NSCLC/INDIA:
2-4-09 PR: “7 of 17 (41%) achieving PR (CR=1)” (after 4 of 6 3wk cycles)
=> 6-3-09 PR: “11 of 17 (64.7) achieving PR” (after 6 of 6 3wk cycles)
= = = = = = = Bavi+Chemo Ph.2 Trial WEEKS CALCS as of 6-2-09:
D. PH.2 BAVI+CP VS. ADV./MET. LUNG CANCER (NSCLC) - INDIA:
http://clinicaltrials.gov/ct2/show/NCT00687817 (21+28=49)
1st-DOSED: 6-30-08 => 48.1wks a/o 6-2-09
ALL-21-ENROLLED-Stage1: 10-20-08 => 32.1wks a/o 6-2-09
1st-DOSED-Stage2(28): 4-20-09 => 6.1wks a/o 6-2-09
= = = = = = = = = =
BAVITUXIMAB SOLID CANCERS PHASE 2 TRIALS:
D. Phase II Bavi+CP Adv./Met. Lung Cancer (NSCLC) in INDIA:
India’s DCGI protocol (init=6-2008): http://clinicaltrials.gov/ct2/show/NCT00687817
…Early Ph.2/Adv.Lung ORR% comp. of Bavi+CP/65% n=17 vs. Avastin+CP/32% n=35.
6-3-09 PR: 11 of 17 (64.7%) of StageA evaluables achieved OR: http://tinyurl.com/pe923n
4-20-09: Prelim. data, 17 evaluables at 18wks (6 of 6 cycles): 8 OR’s = 47% ORR http://tinyurl.com/cwytaf
…Also, Dosing Underway in Stage2 (addl. 28 patients).
2-4-09: Prelim. data, 17 evaluables at 12wks (4 of 6 cycles): 6 PR’s + one C.R. = 41% ORR http://tinyurl.com/dlotdx
10-20-08: 1st-21 enrolled http://tinyurl.com/5wnhog , 6-30-08: 1st-dosed http://tinyurl.com/69aut8
1-22-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2t6k7j
7-11-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yoxpjl
…"21 patients with Adv. NSCLC initially; exp. to 49 if 1st cohort results positive; primary obj: assess overall response."
Another drop in the hat for PPHM, and boy is it nice to see an ASCO award go to them. With a promising cancer drug like Bavituximab...well you would be hard pressed to find another company quite like this one. Anyway here is the post.
---
PR 6-10-09: ASCO Award to UTSW for New Bavi/NSCLC Study
“ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer”
• Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr. David Gerber of UT Southwestern Medical Center
• New Study Complements Ongoing Bavituximab + Carboplatin/Paclitaxel Phase II NSCLC Trial that has Shown Promising Preliminary Results
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=388927
TUSTIN, June 10 2009: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the ASCO Research Foundation has awarded one of its 2009 Career Development Awards to David Gerber, MD, of the University of Texas Southwestern Medical Center for a study of the biologic effects of bavituximab & chemotherapy in patients with advanced lung cancer. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects.
This new study will supplement Peregrine's Phase II clinical trial [India] evaluating bavituximab in combination with carboplatin & paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). In the first cohort of this trial, 11 of 17 evaluable NSCLC patients, or 64.7%, achieved an objective tumor response according to response evaluation criteria in solid tumors (RECIST). Enrollment of an additional 28 NSCLC patients is ongoing.
"We are delighted that the ASCO Research Foundation has selected Dr. Gerber's study for this prestigious award that nicely complements our ongoing Phase II NSCLC trial, which has already shown very promising results," said Steven W. King, president and CEO of Peregrine. "This clinical study should help us to better understand the biological effects of this new class of immunotherapeutic agents and generate data that will help guide the future clinical development and use of bavituximab."
Dr. Gerber, assistant professor at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern, will receive a 3-year award totaling $200,000 to support his original research, A Pilot Study of the Biologic Effects of Chemotherapy Plus Bavituximab in Patients with Advanced Non-Small Cell Lung Cancer. These competitive awards are available to promising physician researchers who are full-time faculty members in a clinical setting at an academic medical center.
Bavituximab is also currently being tested in combination with chemotherapy in two Phase II trials in advanced breast cancer. Preliminary positive results from one of these trials were the subject of an oral presentation at the 2009 ASCO Annual Meeting.
ABOUT PHOSPHATIDYLSERINE (PS)-TARGETING IMMUNOTHERAPIES
The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at http://www.peregrineinc.com.
ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing 3 separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor *snip*
Contacts: GendeLLindheim BioCom Partners
Investors: 800-987-8256, info@peregrineinc.com
Media: Barbara Lindheim, 212-918-4650
*end*
= = = = = = = = =
Recall, on 4-3-09, the NCI Trials website showed UTSW/Dallas being added as a 5th site in the ongoing U.S. Ph.1 Bavi-Mono Solid Tumors trial, with Dr. Gerber as PI:
Ph.1 Trial: “Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies”
Last Updated: April 3, 2009
TRIAL LOCATIONS:
ADDED:
University of Texas SW Medical Center/Dallas - Recruiting
Principal Investigator: David E Gerber, MD
http://clinicaltrials.gov/ct/show/NCT00129337
Dr. David Gerber’s UTSW Profile:
http://www.utsouthwestern.edu/findfac/professional/0,,53487,00.html
Dr. David Gerber authored this 2-2008 article in American Family Physician:
“Targeted Therapies: A New Generation of Cancer Treatments”
DAVID E. GERBER, MD
The two main types of targeted therapy, monoclonal antibodies and small molecule inhibitors, have revolutionized the treatment of cancer. With their distinct mechanisms of action and toxicities, these drugs require new approaches to determine optimal dosing, to assess patient adherence to therapy, and to evaluate treatment effectiveness…
http://www.aafp.org/afp/20080201/contents.html
http://www.aafp.org/afp/20080201/311.html
He has also presented at past ASCO meetings: http://tinyurl.com/d2pgq7
= = = = = = = = = = =
“The ASCO Cancer Foundation Awards $6.1mm to Further Progress Against Cancer”
FOR IMMEDIATE RELEASE: April 15, 2009
http://tinyurl.com/cqhuse
4-15-09, Alexandria, VA: The ASCO Cancer Foundation will award more than $6.1mm to support clinical & translational research designed to improve cancer prevention, treatment and care. The grants will be awarded to 63 researchers at the ASCO’s 45th Annual Meeting in Orlando, May29–June2…
• Translational Research Professorship: $500k, Merrill Egorin, UPitt
• Advanced Clinical Research Awards: $450k, S.Modi/Sloan-Kettering & I.Mellinghoff/Sloan-Kettering
• Career Development Awards: $200k x 11 winners…
Career Development Awards are presented to physicians in their second, third or fourth year as full-time faculty members in a university setting. Each of this year's 11 winners will receive a 3-year grant totaling $200,000 to establish an indep. clinical cancer research program. The 11 2009 recipients are:
. . .
David Gerber, MD – Univ. of Texas, SW Medical Center
“A Pilot Study of the Biologic Effects of Chemotherapy Plus Bavituximab in Patients with Advanced Non-Small Cell Lung Cancer”
. . .
Supporting Organizations:
The 2009 Career Development Awards are supported by: Amgen, Genentech BioOncology (5), Lilly USA, Novartis Oncology, Sanofi-aventis U.S. (2), The Breast Cancer Research Foundation.
About The ASCO Cancer Foundation:
As the charitable arm of the American Society of Clinical Oncology (ASCO), The ASCO Cancer Foundation funds research, education and cancer care programs both in the U.S. and abroad. By harnessing the knowledge of ASCO’s 27,000 oncology professionals, we help deliver physician-approved information directly to those in need. Through these efforts, we improve the lives of those affected by cancer.
= = = = = = = = = = =
EARLY COMPARISONS OF BAVI VS. AVASTIN TRIAL DATA
III. ADV./MET. NSCLC CANCER (India) - MAB + PACLITAXEL/CARBOPLATIN:
Ph.2 Bavi+CP n=17: 64.7% ORR, interim at ~18wks (6 of 6 cycles). http://tinyurl.com/pe923n
• Ph.2 Avastin+CP n=35: 31.5% ORR http://tinyurl.com/b3g4rf (D.H.Johnson)
...”Avastin+CP yielded longer median TTP (7.4 v 4.2 mos.) and a modest increase in survival (17.7 v 14.9 mos.)”
• Ph.2 Antisoma’s ASA404+CP n=30: 37.9% ORR http://tinyurl.com/pcraga
3-18-09/Cowen, P.Lytle comp. to:
• Avastin+CP (Johnson), 31.5% ORR – at best dosage/15mg (n=99 at both dosages) [ 2004 Ph2 http://tinyurl.com/b3g4rf ]
• Avastin+CP (Sandler), 35% ORR (133 of 381) – best resp. reported. [ 2006 Ph2/3 ‘E4599’ http://tinyurl.com/dbvh4e Excl. Squamous**]
**Note: “In prev. clinical experience with Avastin+CP in NSCLC, patients with ‘squamous’ cancer had a higher risk of experiencing life-threatening or fatal pulmonary bleeding. Squamous cells are a kind of cell that form in the lining of the air ducts in the lung. Because of the risk of bleeding attributed to this population, patients with NSCLC classified as predominantly squamous histology were not included in the E4599 trial.” http://tinyurl.com/cfk9ao
- - - - - - - - - - -
**Another Ph.2 NSCLC trial to compare to…
5-21-09: PH.2 RESULTS FOR ANTISOMA’S ASA404+CP VS. NSCLC (N=30): ORR=37.9%
Antisoma announces that the journal Lung Cancer has published the results of a single-arm Ph.2 trial of ASA404 in NSCLC. The trial included patients with both major histological forms of NSCLC: squamous & non-squamous. Positive data from this trial supported the progress of ASA404 into Ph.3 trials in patients with NSCLC of all histologies. ASA404 is a Tumor-Vascular Disrupting Agent (VDA) that destroys tumors by selectively collapsing the tumor blood vessels on which they depend to survive & grow... In the newly published trial, a further 30 similar patients with NSCLC received std. chemo[carboplatin & paclitaxel] + ASA404 at a higher dose of 1800mg. Median survival was 14.9mos… [compared with 8.8mos. in patients receiving chemo alone]… Tumor response rate was 37.9%... TTP was 5.5mos…. Median survival was 14.9mos.
http://tinyurl.com/pcraga
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+DOCE/NSCLC/INDIA:
2-4-09 PR: “7 of 17 (41%) achieving PR (CR=1)” (after 4 of 6 3wk cycles)
=> 6-3-09 PR: “11 of 17 (64.7) achieving PR” (after 6 of 6 3wk cycles)
= = = = = = = Bavi+Chemo Ph.2 Trial WEEKS CALCS as of 6-2-09:
D. PH.2 BAVI+CP VS. ADV./MET. LUNG CANCER (NSCLC) - INDIA:
http://clinicaltrials.gov/ct2/show/NCT00687817 (21+28=49)
1st-DOSED: 6-30-08 => 48.1wks a/o 6-2-09
ALL-21-ENROLLED-Stage1: 10-20-08 => 32.1wks a/o 6-2-09
1st-DOSED-Stage2(28): 4-20-09 => 6.1wks a/o 6-2-09
= = = = = = = = = =
BAVITUXIMAB SOLID CANCERS PHASE 2 TRIALS:
D. Phase II Bavi+CP Adv./Met. Lung Cancer (NSCLC) in INDIA:
India’s DCGI protocol (init=6-2008): http://clinicaltrials.gov/ct2/show/NCT00687817
…Early Ph.2/Adv.Lung ORR% comp. of Bavi+CP/65% n=17 vs. Avastin+CP/32% n=35.
6-3-09 PR: 11 of 17 (64.7%) of StageA evaluables achieved OR: http://tinyurl.com/pe923n
4-20-09: Prelim. data, 17 evaluables at 18wks (6 of 6 cycles): 8 OR’s = 47% ORR http://tinyurl.com/cwytaf
…Also, Dosing Underway in Stage2 (addl. 28 patients).
2-4-09: Prelim. data, 17 evaluables at 12wks (4 of 6 cycles): 6 PR’s + one C.R. = 41% ORR http://tinyurl.com/dlotdx
10-20-08: 1st-21 enrolled http://tinyurl.com/5wnhog , 6-30-08: 1st-dosed http://tinyurl.com/69aut8
1-22-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2t6k7j
7-11-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yoxpjl
…"21 patients with Adv. NSCLC initially; exp. to 49 if 1st cohort results positive; primary obj: assess overall response."
Monday, June 8, 2009
PPHM and amazing cancer treatment results
This was reprinted from investors hub published by cjdaddy on Peregrine Pharmaceuticals (PPHM). His posts are around a lot of stock sites, but I would like to reprint those results here and talk about the results for a moment.
It is difficult to believe the results but these are the facts and the results are better than expected.
I feel this company is a gem in the rough and will be bought up quickly. They are diligent in their research and have deliberately slowed their progress over the years to aggregate the best and cleanest possibly data on their products in development.
If fact, you may never pass by a pharma company like this. The cancer cure ideas coupled with the data make a compelling combination and the shares are at the right price.
So this company is a strong buy.
EARLY COMPARISONS OF BAVI VS. AVASTIN TRIAL DATA
I. ADV./MET. BREAST CANCER (Rep.GA.) – MAB + DOCETAXEL:
Ph.2 Bavi+Doce n=14: 71% ORR (Med.PFS=7.4mos), StageA at ~24wks. http://tinyurl.com/6qx4gp
Ph.2 Avastin+Doce n=27: 52% ORR (Med.PFS=7.5mos) http://tinyurl.com/dnfk4y (B. Ramaswamy)
3-18-09/Cowen, P.Lytle comp. to:
• Avastin+Doce (Ramaswamy), 52% ORR (14 of 27). [ 2006 Ph2 http://tinyurl.com/dnfk4y ]
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+DOCE/BREAST/GA:
6-2-08 PR: “5 of 11 (45%) achieving PR” (1st 11 evaluables, 8wk-scans)
=> 7-2-08 PR: “7 of 14 (50%) achieving PR” (9wks after all S1 enrolled, 8wk-scans)
==> 9-9-08 CC/SK: “9 of 14 (64%) achieving PR” (19wks after all S1 enrolled, ~12/16wk-scans)
===> 10-21-08 PR: “10 of 14 (71%) achieved an ORR.” (after 6 of 6 4wk cycles)
II. ADV./MET. BREAST CANCER (India) - MAB + PACLITAXEL/CARBOPLATIN:
Ph.2 Bavi+CP n=14: 64% ORR, interim ~24wks (6 of 6 cycles). http://tinyurl.com/c9hna4
Ph.3 Avastin+PAC n=347: 37% ORR (Med.PFS=11.8mos) http://tinyurl.com/defllo (HER2+ Excluded!)
...Note: this article tells us ‘No Complete Responses’ in the Avastin Ph.3 trial: http://tinyurl.com/csqcuw
...”Avastin+PAC prolongs progression-free survival, but not overall survival, as compared with PAC alone.”
3-18-09/Cowen, P.Lytle comp. to:
• CP (Fountzilas), 53% ORR (35 of 66) – best resp. reported. [ 1998 Ph2 http://tinyurl.com/d8g8fu ]
• CP (Perez), 62% ORR (33 of 53) – best resp. reported. [ 2000 Ph2 http://tinyurl.com/cxk8yh ]
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+CP/BREAST/INDIA:
2-11-09 PR: “7 of 14 (50%) achieving PR” (after 2 of 6 4wk cycles)
=> 4-27-09 PR: “9 of 14 (64%) achieving PR” (after 6 of 6 4wk cycles)
III. ADV./MET. NSCLC CANCER (India) - MAB + PACLITAXEL/CARBOPLATIN:
Ph.2 Bavi+CP n=17: 64.7% ORR, interim at ~18wks (6 of 6 cycles). http://tinyurl.com/pe923n
• Ph.2 Avastin+CP n=35: 31.5% ORR http://tinyurl.com/b3g4rf (D.H.Johnson)
...”Avastin+CP yielded longer median TTP (7.4 v 4.2 mos.) and a modest increase in survival (17.7 v 14.9 mos.)”
• Ph.2 Antisoma’s ASA404+CP n=30: 37.9% ORR http://tinyurl.com/pcraga
3-18-09/Cowen, P.Lytle comp. to:
• Avastin+CP (Johnson), 31.5% ORR – at best dosage/15mg (n=99 at both dosages) [ 2004 Ph2 http://tinyurl.com/b3g4rf ]
• Avastin+CP (Sandler), 35% ORR (133 of 381) – best resp. reported. [ 2006 Ph2/3 ‘E4599’ http://tinyurl.com/dbvh4e Excl. Squamous**]
**Note: “In prev. clinical experience with Avastin+CP in NSCLC, patients with ‘squamous’ cancer had a higher risk of experiencing life-threatening or fatal pulmonary bleeding. Squamous cells are a kind of cell that form in the lining of the air ducts in the lung. Because of the risk of bleeding attributed to this population, patients with NSCLC classified as predominantly squamous histology were not included in the E4599 trial.” http://tinyurl.com/cfk9ao
- - - - - - - - - - -
**Another Ph.2 NSCLC trial to compare to…
5-21-09: PH.2 RESULTS FOR ANTISOMA’S ASA404+CP VS. NSCLC (N=30): ORR=37.9%
Antisoma announces that the journal Lung Cancer has published the results of a single-arm Ph.2 trial of ASA404 in NSCLC. The trial included patients with both major histological forms of NSCLC: squamous & non-squamous. Positive data from this trial supported the progress of ASA404 into Ph.3 trials in patients with NSCLC of all histologies. ASA404 is a Tumor-Vascular Disrupting Agent (VDA) that destroys tumors by selectively collapsing the tumor blood vessels on which they depend to survive & grow... In the newly published trial, a further 30 similar patients with NSCLC received std. chemo[carboplatin & paclitaxel] + ASA404 at a higher dose of 1800mg. Median survival was 14.9mos… [compared with 8.8mos. in patients receiving chemo alone]… Tumor response rate was 37.9%... TTP was 5.5mos…. Median survival was 14.9mos.
http://tinyurl.com/pcraga
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+DOCE/NSCLC/INDIA:
2-4-09 PR: “7 of 17 (41%) achieving PR (CR=1)” (after 4 of 6 3wk cycles)
=> 6-3-09 PR: “11 of 17 (64.7) achieving PR” (after 6 of 6 3wk cycles)
= = = = = = = Bavi+Chemo Ph.2 Trial WEEKS CALCS as of 6-2-09:
C. PH.2 BAVI+DOCETAXEL VS. ADV./MET. BREAST CANCER - GA:
http://clinicaltrials.gov/ct2/show/NCT00669591 (15+31=46)
1st-DOSED: 2-12-08 => 68.0wks a/o 6-2-09
ALL-15-DOSED-Stage1: 4-29-08 => 57.0wks a/o 6-2-09
1st-Screened-Stage2(31): 10-21-08 => 32.0wks a/o 6-2-09
ALL-31-DOSED-Stage2: 5-4-09 => 4.1wks a/o 6-2-09
D. PH.2 BAVI+CP VS. ADV./MET. LUNG CANCER (NSCLC) - INDIA:
http://clinicaltrials.gov/ct2/show/NCT00687817 (21+28=49)
1st-DOSED: 6-30-08 => 48.1wks a/o 6-2-09
ALL-21-ENROLLED-Stage1: 10-20-08 => 32.1wks a/o 6-2-09
1st-DOSED-Stage2(28): 4-20-09 => 6.1wks a/o 6-2-09
E. PH.2 BAVI+CP VS. ADV./MET. BREAST CANCER - INDIA:
http://clinicaltrials.gov/ct2/show/NCT00669565 (15+31=46)
1st-DOSED: 8-11-08 => 42.1wks a/o 6-2-09
ALL-15-DOSED-Stage1: 10-7-08 => 34.0wks a/o 6-2-09
1st-DOSED-Stage2(31): 4-27-09 => 5.1wks a/o 6-2-09
= = = = = = = = = = = = = PH.2 BAVI DOSING:
Bavi+Doce-BREAST/GA: 6 4wk-cycles of chemo, weekly-bavi (1 prior chemo, but no Doce)
. . . http://clinicaltrials.gov/ct2/show/NCT00669591
Bavi+CP-BREAST/India: 6 4wk-cycles of chemo, weekly-bavi (no prior chemo/immuno/rad)
. . . http://clinicaltrials.gov/ct2/show/NCT00669565
Bavi+CP-LUNG/India: 6 3wk-cycles of chemo, weekly-bavi (no prior chemo/immuno/rad)
. . . http://clinicaltrials.gov/ct2/show/NCT00687817
= = = =
PR 6-3-09: Progress In All 3 Bavi Ph.2 Cancer Trials Highlighted ( http://tinyurl.com/pe923n )
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
• 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer
• 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer
• 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer
• Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment
• Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could Have Broad Anti-Cancer Utility
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=387687
TUSTIN, June 3, 2009: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in 3 separate cancer trials. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects. Bavituximab is currently being tested in combination with chemotherapy in one Phase II trial in advanced lung cancer and two Phase II trials in advanced breast cancer. Recently-reported data highlights from these studies include the following:
• Non-Small Cell Lung Cancer: Bavituximab in Combination with Carboplatin & Paclitaxel
In the Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) patients with locally advanced or metastatic disease, 11 of 17, or almost 65% [ 64.7% ] of evaluable patients in the initial cohort of 21 patients achieved an objective tumor response. These early results, which exceeded the pre-specified endpoint needed to expand the trial, compare very favorably with historical data with chemotherapy alone and are especially encouraging in this hard-to-treat cancer. Patient enrollment and dosing are continuing in the expansion stage of the trial, which will enroll an additional 28 patients for a total of 49 NSCLC patients overall.
• Advanced Breast Cancer: Bavituximab in Combination with Docetaxel
In the Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients, enrollment of the planned 46 patients was recently completed. As reported in an oral presentation at the 2009 ASCO Annual Meeting, 10 of 14, or 71% of evaluable patients in the initial 15-patient cohort demonstrated an objective tumor response. These data exceeded the pre-specified endpoint needed to expand the trial and compare very favorably with historical data with chemotherapy alone. Recent analysis also shows the median progression free survival of the patients enrolled in the first part of the study was 7.4 months, an additional promising early result. Patient dosing and follow-up in this trial are continuing.
• Advanced Breast Cancer: Bavituximab in Combination with Carboplatin & Paclitaxel
In the Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients, 9 of 14, or 64% of evaluable patients in the initial 15-patient cohort achieved an objective tumor response. These data exceeded the pre- specified endpoint needed to expand the trial and compare favorably with historical results with chemotherapy alone. Patient enrollment and dosing are now underway in the expansion stage of the trial, which will enroll an additional 31 patients for a total of 46 advanced breast cancer patients overall.
The primary objective of these multi-center, open-label studies is to assess the overall patient response rate to the combination regimen of bavituximab and chemotherapy according to RECIST criteria. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. The Phase II bavituximab cancer trials have a Simon two-stage design, where an initial cohort of patients is treated and evaluated and then the study is expanded to a second larger cohort of patients if pre-specified criteria are met. All 3 trials surpassed the criteria for expanding enrollment to the second cohort. Enrollment of the expanded cohort is now complete in one trial and is proceeding in the other two trials.
"Having just completed a busy round of successful data presentations and partnering meetings at ASCO [ http://tinyurl.com/mjwlyd ], we are gratified at the level of interest the bavituximab program is now receiving from leading cancer researchers and drug developers," said Steven W. King, president and CEO of Peregrine. "We believe this growing interest reflects our recent progress in successfully advancing all 3 Phase II bavituximab cancer trials, easily surpassing the pre-determined efficacy criteria needed to expand the trials to larger patient cohorts. The trials encompass different cancers and different chemotherapy regimens, yet in all three, preliminary data on tumor responses are very encouraging and compare well with historical experience with chemotherapy alone. With these encouraging results in hand, we look forward to sharing additional data on the entire clinical study populations in the second half of 2009."
ABOUT PHOSPHATIDYLSERINE (PS)-TARGETING IMMUNOTHERAPIES
The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at www.peregrineinc.com.
ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing 3 separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com) , which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com .
Safe Harbor *snip*
Contacts: GendeLLindheim BioCom Partners
Investors: 800-987-8256, info@peregrineinc.com
Media: Barbara Lindheim, 212-918-4650
*end*
= = = = = = = = = =
BAVITUXIMAB SOLID CANCERS PHASE 2 TRIALS:
==> PR=Partial-Resp(30-99% Red.), SD=Stable-Disease(29% Red.-19% Incr.), OR=Obj-Resp(PR+CR)
3-24-09: EST. of Total #Patients treated with Bavi to date (Cancer & Viral): 180. http://tinyurl.com/ctvfnw
6-3-09: Quick, early summary of Bavi-vs-Avastin in our 3 ongoing Ph.2 trials: http://tinyurl.com/oz3fhv
6-3-09: Peregrine highlights progress in all 3 Ph.2 Bavi Cancer Trials: http://tinyurl.com/pe923n
…CEO S.King, “Having just completed a busy round of successful data presentations and partnering meetings at ASCO’09, we are gratified at the level of interest the Bavi pgm is now receiving from leading cancer researchers & drug developers."
E. Phase II Bavi+CP vs. Adv./Met. Breast Cancer in INDIA:
India’s DCGI protocol (init=8-2008): http://clinicaltrials.gov/ct2/show/NCT00669565
…Early ORR% comp. vs. SOC: Bavi+CP/64% n=14, Avastin+PAC/37% Ph.2/ABC n=347
4-27-09: After full 24wk combo regimen, 9 of 14 (64%) achieving OR http://tinyurl.com/c9hna4
…Also, Dosing Underway in Stage2 (addl. 31 patients).
3-12-09 CC, J.Shan: since the 2-11-09 PR, “we have seen addl. tumor responses.” http://tinyurl.com/cwyo6f
2-11-09: At 8wks (of 24wk combo regimen), 7 of 14 (50%) achieving OR, incl. one C.R. http://tinyurl.com/aquf8r
10-7-08: 1st-15 enrolled http://tinyurl.com/47kvj8 , 8-11-08: 1st-dosed http://tinyurl.com/5ogfxa
1-23-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2rks5y
9-10-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yqm8e7
…”15 patients with MBC initially; exp. to 46 if promising results are observed in the 1st cohort; primary obj: assess overall response.”
D. Phase II Bavi+CP Adv./Met. Lung Cancer (NSCLC) in INDIA:
India’s DCGI protocol (init=6-2008): http://clinicaltrials.gov/ct2/show/NCT00687817
…Early Ph.2/Adv.Lung ORR% comp. of Bavi+CP/65% n=17 vs. Avastin+CP/32% n=35.
6-3-09 PR: 11 of 17 (64.7%) of StageA evaluables achieved OR: http://tinyurl.com/pe923n
4-20-09: Prelim. data, 17 evaluables at 18wks (6 of 6 cycles): 8 OR’s = 47% ORR http://tinyurl.com/cwytaf
…Also, Dosing Underway in Stage2 (addl. 28 patients).
2-4-09: Prelim. data, 17 evaluables at 12wks (4 of 6 cycles): 6 PR’s + one C.R. = 41% ORR http://tinyurl.com/dlotdx
10-20-08: 1st-21 enrolled http://tinyurl.com/5wnhog , 6-30-08: 1st-dosed http://tinyurl.com/69aut8
1-22-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2t6k7j
7-11-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yoxpjl
…"21 patients with Adv. NSCLC initially; exp. to 49 if 1st cohort results positive; primary obj: assess overall response."
C. Phase II Bavi+Docetaxel vs. Adv./Met. Breast Cancer in E.EUR.(Georgia):
Georgia Ministry of Health protocol (init=1-2008): http://clinicaltrials.gov/ct2/show/NCT00669591
6-1-09: ASCO’09 oral presentation (StageA/14pts: 71% ORR & 7.4mos.PFS) http://tinyurl.com/mjwlyd
5-4-09: Stage2 Enrollment Complete (15+31=46 total): http://tinyurl.com/cp737p
10-21-08: “10 of 14 (71%) evaluables achieved an objective tumor response.” http://tinyurl.com/6qx4gp
…Mojo’s early comp of Bavi+Doce Ph.2 vs. Avastin+Chemo trials - PFS% chart: http://tinyurl.com/5rergk
9-9-08 SK: “We have now seen addl. patients with tumor responses, with 9 of the 14 evaluables (64%) having achieved PR.” http://tinyurl.com/5q9phf
7-2-08: Ph.2 Bavi+Doce/Breast update. http://tinyurl.com/5tvfhy
…”At 8wks (of 24wk combo regimen), 100% of [1st 14] evaluables showing OR/SD; 7 of 14 (50%) achieving PR”
6-2-08: ASCO/2008 Ph.2 Bavi+Doce/Breast Update: http://tinyurl.com/5xll6f
…”At 8wks (of 24wk combo regimen), 100% of [1st 11] evaluables showing OR/SD; 5 of 11 (45%) achieving PR”
4-29-08: 1st-15 enrolled http://tinyurl.com/47o85x , 2-12-08: 1st-dosed http://tinyurl.com/36c28s , 1-29-08 Enroll. begins http://tinyurl.com/22ecb2
11-16-07: Ph.2 protocol approved. “Patient Enrollment expected by early 2008.” http://tinyurl.com/3aavzh
10-22-07: Protocol Submitted to Ministry of Health, Rep. of Georgia: http://tinyurl.com/2xjjgp
…”15 patients with MBC initially; exp. to 46 if promising results are observed in the 1st cohort; primary obj: assess overall response.”
It is difficult to believe the results but these are the facts and the results are better than expected.
I feel this company is a gem in the rough and will be bought up quickly. They are diligent in their research and have deliberately slowed their progress over the years to aggregate the best and cleanest possibly data on their products in development.
If fact, you may never pass by a pharma company like this. The cancer cure ideas coupled with the data make a compelling combination and the shares are at the right price.
So this company is a strong buy.
EARLY COMPARISONS OF BAVI VS. AVASTIN TRIAL DATA
I. ADV./MET. BREAST CANCER (Rep.GA.) – MAB + DOCETAXEL:
Ph.2 Bavi+Doce n=14: 71% ORR (Med.PFS=7.4mos), StageA at ~24wks. http://tinyurl.com/6qx4gp
Ph.2 Avastin+Doce n=27: 52% ORR (Med.PFS=7.5mos) http://tinyurl.com/dnfk4y (B. Ramaswamy)
3-18-09/Cowen, P.Lytle comp. to:
• Avastin+Doce (Ramaswamy), 52% ORR (14 of 27). [ 2006 Ph2 http://tinyurl.com/dnfk4y ]
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+DOCE/BREAST/GA:
6-2-08 PR: “5 of 11 (45%) achieving PR” (1st 11 evaluables, 8wk-scans)
=> 7-2-08 PR: “7 of 14 (50%) achieving PR” (9wks after all S1 enrolled, 8wk-scans)
==> 9-9-08 CC/SK: “9 of 14 (64%) achieving PR” (19wks after all S1 enrolled, ~12/16wk-scans)
===> 10-21-08 PR: “10 of 14 (71%) achieved an ORR.” (after 6 of 6 4wk cycles)
II. ADV./MET. BREAST CANCER (India) - MAB + PACLITAXEL/CARBOPLATIN:
Ph.2 Bavi+CP n=14: 64% ORR, interim ~24wks (6 of 6 cycles). http://tinyurl.com/c9hna4
Ph.3 Avastin+PAC n=347: 37% ORR (Med.PFS=11.8mos) http://tinyurl.com/defllo (HER2+ Excluded!)
...Note: this article tells us ‘No Complete Responses’ in the Avastin Ph.3 trial: http://tinyurl.com/csqcuw
...”Avastin+PAC prolongs progression-free survival, but not overall survival, as compared with PAC alone.”
3-18-09/Cowen, P.Lytle comp. to:
• CP (Fountzilas), 53% ORR (35 of 66) – best resp. reported. [ 1998 Ph2 http://tinyurl.com/d8g8fu ]
• CP (Perez), 62% ORR (33 of 53) – best resp. reported. [ 2000 Ph2 http://tinyurl.com/cxk8yh ]
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+CP/BREAST/INDIA:
2-11-09 PR: “7 of 14 (50%) achieving PR” (after 2 of 6 4wk cycles)
=> 4-27-09 PR: “9 of 14 (64%) achieving PR” (after 6 of 6 4wk cycles)
III. ADV./MET. NSCLC CANCER (India) - MAB + PACLITAXEL/CARBOPLATIN:
Ph.2 Bavi+CP n=17: 64.7% ORR, interim at ~18wks (6 of 6 cycles). http://tinyurl.com/pe923n
• Ph.2 Avastin+CP n=35: 31.5% ORR http://tinyurl.com/b3g4rf (D.H.Johnson)
...”Avastin+CP yielded longer median TTP (7.4 v 4.2 mos.) and a modest increase in survival (17.7 v 14.9 mos.)”
• Ph.2 Antisoma’s ASA404+CP n=30: 37.9% ORR http://tinyurl.com/pcraga
3-18-09/Cowen, P.Lytle comp. to:
• Avastin+CP (Johnson), 31.5% ORR – at best dosage/15mg (n=99 at both dosages) [ 2004 Ph2 http://tinyurl.com/b3g4rf ]
• Avastin+CP (Sandler), 35% ORR (133 of 381) – best resp. reported. [ 2006 Ph2/3 ‘E4599’ http://tinyurl.com/dbvh4e Excl. Squamous**]
**Note: “In prev. clinical experience with Avastin+CP in NSCLC, patients with ‘squamous’ cancer had a higher risk of experiencing life-threatening or fatal pulmonary bleeding. Squamous cells are a kind of cell that form in the lining of the air ducts in the lung. Because of the risk of bleeding attributed to this population, patients with NSCLC classified as predominantly squamous histology were not included in the E4599 trial.” http://tinyurl.com/cfk9ao
- - - - - - - - - - -
**Another Ph.2 NSCLC trial to compare to…
5-21-09: PH.2 RESULTS FOR ANTISOMA’S ASA404+CP VS. NSCLC (N=30): ORR=37.9%
Antisoma announces that the journal Lung Cancer has published the results of a single-arm Ph.2 trial of ASA404 in NSCLC. The trial included patients with both major histological forms of NSCLC: squamous & non-squamous. Positive data from this trial supported the progress of ASA404 into Ph.3 trials in patients with NSCLC of all histologies. ASA404 is a Tumor-Vascular Disrupting Agent (VDA) that destroys tumors by selectively collapsing the tumor blood vessels on which they depend to survive & grow... In the newly published trial, a further 30 similar patients with NSCLC received std. chemo[carboplatin & paclitaxel] + ASA404 at a higher dose of 1800mg. Median survival was 14.9mos… [compared with 8.8mos. in patients receiving chemo alone]… Tumor response rate was 37.9%... TTP was 5.5mos…. Median survival was 14.9mos.
http://tinyurl.com/pcraga
- - - - - - - - -
ORR% UPDATE HISTORY FOR PH.2/BAVI+DOCE/NSCLC/INDIA:
2-4-09 PR: “7 of 17 (41%) achieving PR (CR=1)” (after 4 of 6 3wk cycles)
=> 6-3-09 PR: “11 of 17 (64.7) achieving PR” (after 6 of 6 3wk cycles)
= = = = = = = Bavi+Chemo Ph.2 Trial WEEKS CALCS as of 6-2-09:
C. PH.2 BAVI+DOCETAXEL VS. ADV./MET. BREAST CANCER - GA:
http://clinicaltrials.gov/ct2/show/NCT00669591 (15+31=46)
1st-DOSED: 2-12-08 => 68.0wks a/o 6-2-09
ALL-15-DOSED-Stage1: 4-29-08 => 57.0wks a/o 6-2-09
1st-Screened-Stage2(31): 10-21-08 => 32.0wks a/o 6-2-09
ALL-31-DOSED-Stage2: 5-4-09 => 4.1wks a/o 6-2-09
D. PH.2 BAVI+CP VS. ADV./MET. LUNG CANCER (NSCLC) - INDIA:
http://clinicaltrials.gov/ct2/show/NCT00687817 (21+28=49)
1st-DOSED: 6-30-08 => 48.1wks a/o 6-2-09
ALL-21-ENROLLED-Stage1: 10-20-08 => 32.1wks a/o 6-2-09
1st-DOSED-Stage2(28): 4-20-09 => 6.1wks a/o 6-2-09
E. PH.2 BAVI+CP VS. ADV./MET. BREAST CANCER - INDIA:
http://clinicaltrials.gov/ct2/show/NCT00669565 (15+31=46)
1st-DOSED: 8-11-08 => 42.1wks a/o 6-2-09
ALL-15-DOSED-Stage1: 10-7-08 => 34.0wks a/o 6-2-09
1st-DOSED-Stage2(31): 4-27-09 => 5.1wks a/o 6-2-09
= = = = = = = = = = = = = PH.2 BAVI DOSING:
Bavi+Doce-BREAST/GA: 6 4wk-cycles of chemo, weekly-bavi (1 prior chemo, but no Doce)
. . . http://clinicaltrials.gov/ct2/show/NCT00669591
Bavi+CP-BREAST/India: 6 4wk-cycles of chemo, weekly-bavi (no prior chemo/immuno/rad)
. . . http://clinicaltrials.gov/ct2/show/NCT00669565
Bavi+CP-LUNG/India: 6 3wk-cycles of chemo, weekly-bavi (no prior chemo/immuno/rad)
. . . http://clinicaltrials.gov/ct2/show/NCT00687817
= = = =
PR 6-3-09: Progress In All 3 Bavi Ph.2 Cancer Trials Highlighted ( http://tinyurl.com/pe923n )
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
• 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer
• 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer
• 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer
• Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment
• Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could Have Broad Anti-Cancer Utility
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=387687
TUSTIN, June 3, 2009: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in 3 separate cancer trials. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects. Bavituximab is currently being tested in combination with chemotherapy in one Phase II trial in advanced lung cancer and two Phase II trials in advanced breast cancer. Recently-reported data highlights from these studies include the following:
• Non-Small Cell Lung Cancer: Bavituximab in Combination with Carboplatin & Paclitaxel
In the Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) patients with locally advanced or metastatic disease, 11 of 17, or almost 65% [ 64.7% ] of evaluable patients in the initial cohort of 21 patients achieved an objective tumor response. These early results, which exceeded the pre-specified endpoint needed to expand the trial, compare very favorably with historical data with chemotherapy alone and are especially encouraging in this hard-to-treat cancer. Patient enrollment and dosing are continuing in the expansion stage of the trial, which will enroll an additional 28 patients for a total of 49 NSCLC patients overall.
• Advanced Breast Cancer: Bavituximab in Combination with Docetaxel
In the Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients, enrollment of the planned 46 patients was recently completed. As reported in an oral presentation at the 2009 ASCO Annual Meeting, 10 of 14, or 71% of evaluable patients in the initial 15-patient cohort demonstrated an objective tumor response. These data exceeded the pre-specified endpoint needed to expand the trial and compare very favorably with historical data with chemotherapy alone. Recent analysis also shows the median progression free survival of the patients enrolled in the first part of the study was 7.4 months, an additional promising early result. Patient dosing and follow-up in this trial are continuing.
• Advanced Breast Cancer: Bavituximab in Combination with Carboplatin & Paclitaxel
In the Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients, 9 of 14, or 64% of evaluable patients in the initial 15-patient cohort achieved an objective tumor response. These data exceeded the pre- specified endpoint needed to expand the trial and compare favorably with historical results with chemotherapy alone. Patient enrollment and dosing are now underway in the expansion stage of the trial, which will enroll an additional 31 patients for a total of 46 advanced breast cancer patients overall.
The primary objective of these multi-center, open-label studies is to assess the overall patient response rate to the combination regimen of bavituximab and chemotherapy according to RECIST criteria. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. The Phase II bavituximab cancer trials have a Simon two-stage design, where an initial cohort of patients is treated and evaluated and then the study is expanded to a second larger cohort of patients if pre-specified criteria are met. All 3 trials surpassed the criteria for expanding enrollment to the second cohort. Enrollment of the expanded cohort is now complete in one trial and is proceeding in the other two trials.
"Having just completed a busy round of successful data presentations and partnering meetings at ASCO [ http://tinyurl.com/mjwlyd ], we are gratified at the level of interest the bavituximab program is now receiving from leading cancer researchers and drug developers," said Steven W. King, president and CEO of Peregrine. "We believe this growing interest reflects our recent progress in successfully advancing all 3 Phase II bavituximab cancer trials, easily surpassing the pre-determined efficacy criteria needed to expand the trials to larger patient cohorts. The trials encompass different cancers and different chemotherapy regimens, yet in all three, preliminary data on tumor responses are very encouraging and compare well with historical experience with chemotherapy alone. With these encouraging results in hand, we look forward to sharing additional data on the entire clinical study populations in the second half of 2009."
ABOUT PHOSPHATIDYLSERINE (PS)-TARGETING IMMUNOTHERAPIES
The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the tumor blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at www.peregrineinc.com.
ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing 3 separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com) , which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com .
Safe Harbor *snip*
Contacts: GendeLLindheim BioCom Partners
Investors: 800-987-8256, info@peregrineinc.com
Media: Barbara Lindheim, 212-918-4650
*end*
= = = = = = = = = =
BAVITUXIMAB SOLID CANCERS PHASE 2 TRIALS:
==> PR=Partial-Resp(30-99% Red.), SD=Stable-Disease(29% Red.-19% Incr.), OR=Obj-Resp(PR+CR)
3-24-09: EST. of Total #Patients treated with Bavi to date (Cancer & Viral): 180. http://tinyurl.com/ctvfnw
6-3-09: Quick, early summary of Bavi-vs-Avastin in our 3 ongoing Ph.2 trials: http://tinyurl.com/oz3fhv
6-3-09: Peregrine highlights progress in all 3 Ph.2 Bavi Cancer Trials: http://tinyurl.com/pe923n
…CEO S.King, “Having just completed a busy round of successful data presentations and partnering meetings at ASCO’09, we are gratified at the level of interest the Bavi pgm is now receiving from leading cancer researchers & drug developers."
E. Phase II Bavi+CP vs. Adv./Met. Breast Cancer in INDIA:
India’s DCGI protocol (init=8-2008): http://clinicaltrials.gov/ct2/show/NCT00669565
…Early ORR% comp. vs. SOC: Bavi+CP/64% n=14, Avastin+PAC/37% Ph.2/ABC n=347
4-27-09: After full 24wk combo regimen, 9 of 14 (64%) achieving OR http://tinyurl.com/c9hna4
…Also, Dosing Underway in Stage2 (addl. 31 patients).
3-12-09 CC, J.Shan: since the 2-11-09 PR, “we have seen addl. tumor responses.” http://tinyurl.com/cwyo6f
2-11-09: At 8wks (of 24wk combo regimen), 7 of 14 (50%) achieving OR, incl. one C.R. http://tinyurl.com/aquf8r
10-7-08: 1st-15 enrolled http://tinyurl.com/47kvj8 , 8-11-08: 1st-dosed http://tinyurl.com/5ogfxa
1-23-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2rks5y
9-10-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yqm8e7
…”15 patients with MBC initially; exp. to 46 if promising results are observed in the 1st cohort; primary obj: assess overall response.”
D. Phase II Bavi+CP Adv./Met. Lung Cancer (NSCLC) in INDIA:
India’s DCGI protocol (init=6-2008): http://clinicaltrials.gov/ct2/show/NCT00687817
…Early Ph.2/Adv.Lung ORR% comp. of Bavi+CP/65% n=17 vs. Avastin+CP/32% n=35.
6-3-09 PR: 11 of 17 (64.7%) of StageA evaluables achieved OR: http://tinyurl.com/pe923n
4-20-09: Prelim. data, 17 evaluables at 18wks (6 of 6 cycles): 8 OR’s = 47% ORR http://tinyurl.com/cwytaf
…Also, Dosing Underway in Stage2 (addl. 28 patients).
2-4-09: Prelim. data, 17 evaluables at 12wks (4 of 6 cycles): 6 PR’s + one C.R. = 41% ORR http://tinyurl.com/dlotdx
10-20-08: 1st-21 enrolled http://tinyurl.com/5wnhog , 6-30-08: 1st-dosed http://tinyurl.com/69aut8
1-22-08: Ph.2 protocol approved by DCGI, “looking fwd to study initiation in the near future.” http://tinyurl.com/2t6k7j
7-11-07: Protocol Submitted to Indian Drug Controller General: http://tinyurl.com/yoxpjl
…"21 patients with Adv. NSCLC initially; exp. to 49 if 1st cohort results positive; primary obj: assess overall response."
C. Phase II Bavi+Docetaxel vs. Adv./Met. Breast Cancer in E.EUR.(Georgia):
Georgia Ministry of Health protocol (init=1-2008): http://clinicaltrials.gov/ct2/show/NCT00669591
6-1-09: ASCO’09 oral presentation (StageA/14pts: 71% ORR & 7.4mos.PFS) http://tinyurl.com/mjwlyd
5-4-09: Stage2 Enrollment Complete (15+31=46 total): http://tinyurl.com/cp737p
10-21-08: “10 of 14 (71%) evaluables achieved an objective tumor response.” http://tinyurl.com/6qx4gp
…Mojo’s early comp of Bavi+Doce Ph.2 vs. Avastin+Chemo trials - PFS% chart: http://tinyurl.com/5rergk
9-9-08 SK: “We have now seen addl. patients with tumor responses, with 9 of the 14 evaluables (64%) having achieved PR.” http://tinyurl.com/5q9phf
7-2-08: Ph.2 Bavi+Doce/Breast update. http://tinyurl.com/5tvfhy
…”At 8wks (of 24wk combo regimen), 100% of [1st 14] evaluables showing OR/SD; 7 of 14 (50%) achieving PR”
6-2-08: ASCO/2008 Ph.2 Bavi+Doce/Breast Update: http://tinyurl.com/5xll6f
…”At 8wks (of 24wk combo regimen), 100% of [1st 11] evaluables showing OR/SD; 5 of 11 (45%) achieving PR”
4-29-08: 1st-15 enrolled http://tinyurl.com/47o85x , 2-12-08: 1st-dosed http://tinyurl.com/36c28s , 1-29-08 Enroll. begins http://tinyurl.com/22ecb2
11-16-07: Ph.2 protocol approved. “Patient Enrollment expected by early 2008.” http://tinyurl.com/3aavzh
10-22-07: Protocol Submitted to Ministry of Health, Rep. of Georgia: http://tinyurl.com/2xjjgp
…”15 patients with MBC initially; exp. to 46 if promising results are observed in the 1st cohort; primary obj: assess overall response.”
Sunday, September 21, 2008
What is shiny, available in November, and worth 400 shares?
Activision Blizzard’s latest episode in the World of Warcraft Franschise: Wrath of the Lich King’s final release date of November 13! Yes the money printing machine is getting oiled and test sheets are being printed.
Company: ATVI
In a world where companies are either releasing new shares or reverse splitting to shore up their stock price, or looking for capital…I have a company that ‘prints it’s own money’, yes even in today’s wintery economy.
ATVI Activision Blizzard is a buy after a 2:1 split from the high 30’s and the Shares floating between 16-17 dollars a share a bullish indicator if ever there was one.
This company with the popular franchises like World of Warcraft, Diablo, Starcraft which many are familiar have three (possibly four releases coming up in the next two years).
We are not even factoring in Guitar hero stuff or anything for that matter on the Activision side.
First lets get an over view at the technical and fundamentals:
IBD gives ATVI an over all A-
The Volume Change has gone up 24%
And I have never…never seen this before on IDB:
Overall Rank : 100%
Technical Rank : 100%
Fundamental Rank : 100%
Attractiveness Rank : 100%
For a ‘group’s’ technical ranking that at a 42 = D
If ne knows nothing about MMORPG games, or non-MMO games everyone has heard of Blizzard and knows their reputation for the BEST computer based video games for 10 the last ten years and Activision (who doesn’t remember the DOOM/QUAKE franchise).
Activision has a primary focus on Console games and some PC/MAC games like Call of Duty. But they are about to change the landscape of the console game world.
Here is what the CEO had to say:
Kotick was speaking during the Activision Blizzard Analyst Day in Los Angeles, where he added that he expects the PlayStation 3 to remain on the market for at least eight years.
"Now that we have the weight of being the largest payer of royalties to the first-parties of any third-party company, I definitely see us as starting to influence hardware design, and they're thinking about the evolution of the next generation of hardware," he said.
"The good news is that when it does come it's going to have a powerful impact on our ability to capture a lot of that part of the marketplace today that feature films, television or music [inhabit]."
Activision has enjoyed tremendous success with the Guitar Hero franchise, a retail game supported by sales of multiple downloadable content and its own peripheral hardware.
"The better news for us right now is it's going to happen a lot longer from now than we've seen with prior generations, because the power and the capability of the hardware we have today is so strong, and the differentiation between the devices is so great that you're likely to see this cycle last a lot longer than we've seen in the past," continued Kotick.
"I think there's a long life ahead of us, we're in year eight of PlayStation 2 and when you look at PlayStation 3 technically we're likely to see at least eight years' success."
The CEO also suggested that current home consoles are still not yet appealingly priced for true mass market adoption, and that he expects mainstream consumers will buy into videogames over the next couple of years.
"We're about to enter the next phase of the console opportunity – that is where price points are starting to achieve mass market-level price points," he offered.
Where the rubber meets the road…
MorningStar info:
Total Revenue: $3.05 Billion compared to 35 million for the industry as a whole.
In 2007 this stock pulled 72.3% growth. YTD we are to 17.9 percent so far.
The industry grew 57% and 43% YTD.
Motley fool CAPS has 13 Bullish reviews and only 2 (uninformative) bearish reviews.
This company has a 10 return of 34.3. This might not seem immediately interesting until you factor in the “Blizzard effect”. Activision bought Blizzard a few months back and the stock flew up around $10.
Forward Earnings Yield
ATVI: 8.4
Industry: 2.29
S&P 500: 7.3
Forward P/E
ATVI: 11.9
Industry: 43.8
S&P 500: 13.7
Price/Cash Flow
ATVI: 8.0
Industry: 0.2
S&P 500: 12.1
Price/Sales
ATVI: 0.9
Industry: 0.0
S&P 500: 2.4
I want to talk about this earnings yield because I am more interested in that figure. It is wrong and should be higher. The reason for this is that World of Warcraft 3 is a subscription based product.
Louis Navellier gives a total stock a rating of a B. In one category in particular he gives it an A. The category is: Quantitative Grade: (This grade is calculated using a proprietary measure exclusive to the Navellier PortfolioGrader system. The most powerful variable in the stock grading system, the Quantitative Grade rewards stocks that have been outperforming the market on a risk-adjusted basis. Stocks that have been under performing the market and have been volatile will receive lower grades, while stocks that have been generating steady returns will receive higher grades.)
S&P Stock report gives it three stars and marks it as Hold.
Here is the problem with all the data out their. It is looking to much at Activision, which since 1979 has made great strides in the industry, but with Blizzard under its wing it will expand its dominance and reputation.
This November Blizzard will release the third expansion of World of Warcraft called the Wrath of the Lich King. Now, when they releases that subscriptions will increase, and the expance will go for around $27, so here is a MMO Chart that shows subscriptions of games that have greater than 200,000 subscribers:
http://www.mmogchart.com/Chart1_files/Subscriptions_8846_image001.png
Each one of those 10 million subscribers pays $14 a month. So each month Blizzard brings in $1.4 billion a month. There is lots of anticipation for this release and the beta testers have been posting very positive reviews.
Activision Investor information
Motley Fool
Get Rich with Growth
MorningStar
Quarter 1 results (after merger)
Here are the funds that have involvement with ATVI
Short sell interest
Look at the historical seasonal activity for ATVI
If you can get Reuters Company Research on ATVI read it over it has some great info.
In conclusion: Activision Blizzard is a strong team that will continue to dominate the market compared to it peers and trust me it’s peers are scared shitless and shaken up by this new domination. Don’t underestimate their ability to print their own money as they continue to expand in to Asia, Latin America and Europe as we will get the release first.
Now is the time to buy.
Because we will see a bump BEFORE the November release. We will see upward growth into Guitar hero releases, and then Starcraft is 80% complete. (but as a developer, we all know that the hardest work comes in the last 20% of development). This game will most likely see a release next year Q4, in my opinion. Then comes Diablo 3…Look out, because when that game is released, every gamer in the last 14 years will activate and buy it. That will take them into Q4 2010 and by that time I expect the stock sitting at $50 a share in 2010.
I haven’t even considered of factored in Vivendi into this picture. Vivendi is famous for the Half-Life series…One of the best game in history.
Company: ATVI
In a world where companies are either releasing new shares or reverse splitting to shore up their stock price, or looking for capital…I have a company that ‘prints it’s own money’, yes even in today’s wintery economy.
ATVI Activision Blizzard is a buy after a 2:1 split from the high 30’s and the Shares floating between 16-17 dollars a share a bullish indicator if ever there was one.
This company with the popular franchises like World of Warcraft, Diablo, Starcraft which many are familiar have three (possibly four releases coming up in the next two years).
We are not even factoring in Guitar hero stuff or anything for that matter on the Activision side.
First lets get an over view at the technical and fundamentals:
IBD gives ATVI an over all A-
The Volume Change has gone up 24%
And I have never…never seen this before on IDB:
Overall Rank : 100%
Technical Rank : 100%
Fundamental Rank : 100%
Attractiveness Rank : 100%
For a ‘group’s’ technical ranking that at a 42 = D
If ne knows nothing about MMORPG games, or non-MMO games everyone has heard of Blizzard and knows their reputation for the BEST computer based video games for 10 the last ten years and Activision (who doesn’t remember the DOOM/QUAKE franchise).
Activision has a primary focus on Console games and some PC/MAC games like Call of Duty. But they are about to change the landscape of the console game world.
Here is what the CEO had to say:
Kotick was speaking during the Activision Blizzard Analyst Day in Los Angeles, where he added that he expects the PlayStation 3 to remain on the market for at least eight years.
"Now that we have the weight of being the largest payer of royalties to the first-parties of any third-party company, I definitely see us as starting to influence hardware design, and they're thinking about the evolution of the next generation of hardware," he said.
"The good news is that when it does come it's going to have a powerful impact on our ability to capture a lot of that part of the marketplace today that feature films, television or music [inhabit]."
Activision has enjoyed tremendous success with the Guitar Hero franchise, a retail game supported by sales of multiple downloadable content and its own peripheral hardware.
"The better news for us right now is it's going to happen a lot longer from now than we've seen with prior generations, because the power and the capability of the hardware we have today is so strong, and the differentiation between the devices is so great that you're likely to see this cycle last a lot longer than we've seen in the past," continued Kotick.
"I think there's a long life ahead of us, we're in year eight of PlayStation 2 and when you look at PlayStation 3 technically we're likely to see at least eight years' success."
The CEO also suggested that current home consoles are still not yet appealingly priced for true mass market adoption, and that he expects mainstream consumers will buy into videogames over the next couple of years.
"We're about to enter the next phase of the console opportunity – that is where price points are starting to achieve mass market-level price points," he offered.
Where the rubber meets the road…
MorningStar info:
Total Revenue: $3.05 Billion compared to 35 million for the industry as a whole.
In 2007 this stock pulled 72.3% growth. YTD we are to 17.9 percent so far.
The industry grew 57% and 43% YTD.
Motley fool CAPS has 13 Bullish reviews and only 2 (uninformative) bearish reviews.
This company has a 10 return of 34.3. This might not seem immediately interesting until you factor in the “Blizzard effect”. Activision bought Blizzard a few months back and the stock flew up around $10.
Forward Earnings Yield
ATVI: 8.4
Industry: 2.29
S&P 500: 7.3
Forward P/E
ATVI: 11.9
Industry: 43.8
S&P 500: 13.7
Price/Cash Flow
ATVI: 8.0
Industry: 0.2
S&P 500: 12.1
Price/Sales
ATVI: 0.9
Industry: 0.0
S&P 500: 2.4
I want to talk about this earnings yield because I am more interested in that figure. It is wrong and should be higher. The reason for this is that World of Warcraft 3 is a subscription based product.
Louis Navellier gives a total stock a rating of a B. In one category in particular he gives it an A. The category is: Quantitative Grade: (This grade is calculated using a proprietary measure exclusive to the Navellier PortfolioGrader system. The most powerful variable in the stock grading system, the Quantitative Grade rewards stocks that have been outperforming the market on a risk-adjusted basis. Stocks that have been under performing the market and have been volatile will receive lower grades, while stocks that have been generating steady returns will receive higher grades.)
S&P Stock report gives it three stars and marks it as Hold.
Here is the problem with all the data out their. It is looking to much at Activision, which since 1979 has made great strides in the industry, but with Blizzard under its wing it will expand its dominance and reputation.
This November Blizzard will release the third expansion of World of Warcraft called the Wrath of the Lich King. Now, when they releases that subscriptions will increase, and the expance will go for around $27, so here is a MMO Chart that shows subscriptions of games that have greater than 200,000 subscribers:
http://www.mmogchart.com/Chart1_files/Subscriptions_8846_image001.png
Each one of those 10 million subscribers pays $14 a month. So each month Blizzard brings in $1.4 billion a month. There is lots of anticipation for this release and the beta testers have been posting very positive reviews.
Activision Investor information
Motley Fool
Get Rich with Growth
MorningStar
Quarter 1 results (after merger)
Here are the funds that have involvement with ATVI
Short sell interest
Look at the historical seasonal activity for ATVI
If you can get Reuters Company Research on ATVI read it over it has some great info.
In conclusion: Activision Blizzard is a strong team that will continue to dominate the market compared to it peers and trust me it’s peers are scared shitless and shaken up by this new domination. Don’t underestimate their ability to print their own money as they continue to expand in to Asia, Latin America and Europe as we will get the release first.
Now is the time to buy.
Because we will see a bump BEFORE the November release. We will see upward growth into Guitar hero releases, and then Starcraft is 80% complete. (but as a developer, we all know that the hardest work comes in the last 20% of development). This game will most likely see a release next year Q4, in my opinion. Then comes Diablo 3…Look out, because when that game is released, every gamer in the last 14 years will activate and buy it. That will take them into Q4 2010 and by that time I expect the stock sitting at $50 a share in 2010.
I haven’t even considered of factored in Vivendi into this picture. Vivendi is famous for the Half-Life series…One of the best game in history.
Saturday, August 16, 2008
I'm Back
After I got discouraged with some other traders bashing me and general exhaustion with the market situation, I killed my site (and lost all my posts and links, which was retarded in it's own right). I guess I should just man up.
So lets get back to business.
Financials:
I hate financials. As we know they are mystery companies and pretty much have a knack for manipulation. As this credit crunch/ housing debacle unwinds itself, those companies are basically do all the Due Diligence for us. We are starting to see which are more rooted in filthy subprime debt and who are not.
Bank of America (BAC) This company got bashed all the way down to $18.44. This is basically a solid value play.
There is also no disputing that the XLF is acting more bullish. Be we should really wait till after September/October to know for sure.
Conglomerates:
GE is solid and coming off it's 52 week low of $22 in a very stable and predictable way. It is at $29 and some change now.
Retail:
We love retail so I am going to provide two:
JC Penny: JPC is very bullish considering this wintery economy
Radioshack RSH: man I have not seen a stronger company in a long time. They have over 6000 stores nation wide and they are redesigning each store's layout. It is Radioshack's time to shine again.
That's all for now...
Frank
So lets get back to business.
Financials:
I hate financials. As we know they are mystery companies and pretty much have a knack for manipulation. As this credit crunch/ housing debacle unwinds itself, those companies are basically do all the Due Diligence for us. We are starting to see which are more rooted in filthy subprime debt and who are not.
Bank of America (BAC) This company got bashed all the way down to $18.44. This is basically a solid value play.
There is also no disputing that the XLF is acting more bullish. Be we should really wait till after September/October to know for sure.
Conglomerates:
GE is solid and coming off it's 52 week low of $22 in a very stable and predictable way. It is at $29 and some change now.
Retail:
We love retail so I am going to provide two:
JC Penny: JPC is very bullish considering this wintery economy
Radioshack RSH: man I have not seen a stronger company in a long time. They have over 6000 stores nation wide and they are redesigning each store's layout. It is Radioshack's time to shine again.
That's all for now...
Frank
Subscribe to:
Posts (Atom)
